CME Group (CME) FY2024 10-K Annual Report
CME Group (CME) 10-K annual report for fiscal year 2024, filed with SEC EDGAR on Feb 27, 2025. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
CME Group FY2024 10-K Analysis
Business Overview
- • Core business model: Global derivatives marketplace enabling trading across asset classes including futures and options
- • No new products, services, or business segments introduced or emphasized in this filing year
- • No stated strategic shifts or changes in competitive positioning compared to prior year
- • Equity compensation plans authorized 14.8M shares available for future grants as of December 31, 2024
- • Filing includes recent amendments to stock plans and deferred savings plans effective through 2024 and multiple credit agreement amendments up to April 2024
Management Discussion & Analysis
- • Revenue $6.13B, up 10% YoY from $5.58B, driven by 9% volume growth in clearing and transaction fees
- • Operating margin 64.1% vs 61.6%, net income $3.53B up 9% YoY
- • Best performing segment: Clearing & transaction fees $4.99B, up 9%; worst: cash markets transaction fees down 3% to $276.7M
- • Operating cash flow $3.69B up 7%, capital expenditures $90M forecasted for 2025, dividends approx. $455M quarterly, $5.80/share annual variable dividend paid, $3B share repurchase authorized (none used)
- • 2025 outlook cautious due to inflation uncertainty, Fed guidance, geopolitical tensions impacting volatility and volumes; risks include regulatory environment, market competition, and execution of technology projects
Risk Factors
- • Regulatory risk from failure to maintain BrokerTec Americas' FICC membership, requiring timely margin payments to avoid loss of customer trust and trading volumes
- • Geopolitical exposure to regulatory changes in U.S., U.K., and E.U. jurisdictions impacting compliance costs and business structure globally
- • Operational risk of liquidity shortfall at BrokerTec Americas affecting its ability to meet margin calls under FICC rules
- • Competitive risk from potential transaction taxes proposed domestically and internationally increasing market participant costs, reducing trading activity
- • Financial risk linked to significant compliance cost increases from expanding regulatory oversight impacting operating results
CME Group FY2024 Key Financial MetricsXBRL
Revenue
$6.1B
▲ +9.9% YoY
Net Income
$3.5B
▲ +9.3% YoY
Operating Margin
64.1%
▲ +255bp YoY
Net Margin
57.5%
▼ -31bp YoY
ROE
13.3%
▲ +125bp YoY
Total Assets
$137.4B
▲ +6.0% YoY
EPS (Diluted)
$9.67
▲ +9.1% YoY
Operating Cash Flow
$3.7B
▲ +6.9% YoY
Source: XBRL data from CME Group FY2024 10-K filing on SEC EDGAR. All figures in USD.
Other CME Group Annual Reports
Get deeper insights on CME Group
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.